IGC Pharma
26 hedge funds and large institutions have $1.31M invested in IGC Pharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.
338% more call options, than puts
Call options by funds: $197K | Put options by funds: $45K
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.52% less ownership
Funds ownership: 6.33% → 5.81% (-0.52%)
10% less funds holding
Funds holding: 29 → 26 (-3)
24% less capital invested
Capital invested by funds: $1.73M → $1.31M (-$422K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55K |
| 2 |
Millennium Management
New York
|
+$43.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$19.9K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$7K |
| 5 |
DP
Dearborn Partners
Chicago,
Illinois
|
+$5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$60.5K |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$54K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$37.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.2K |
| 5 |
VF
Virtu Financial
New York
|
-$24K |
IGC Hedge Fund Activity: Q3 2022 in Review
26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2022, worth a combined $1.31M — down 24% from $1.73M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IGC and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $55K. The largest seller was Citadel Advisors, cutting an estimated $60.5K.
- 26 institutional investors held IGC Pharma (IGC) as of Q3 2022, down from 29 in Q2 2022.
- Funds reported $1.31M of IGC Pharma stock for Q3 2022, down 24% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q3 2022 and 7 closed out, a net change of -3 holders.
- The largest IGC Pharma buyer in Q3 2022 was Renaissance Technologies, an estimated $55K added.
- The largest IGC Pharma seller in Q3 2022 was Citadel Advisors, an estimated $60.5K sold.
Based on aggregated 13F filings for Q3 2022.